1. Membrane Transporter/Ion Channel Apoptosis
  2. VDAC Ferroptosis
  3. Erastin

Erastine est un inducteur de ferroptose. Erastine se lie et inhibe les canaux anioniques dépendants de la tension (VDAC2/VDAC3).

Erastin ist ein Ferroptose-Induktor. Erastin bindet und hemmt spannungsabhängige Anionenkanäle (VDAC2/VDAC3).

Erastin is a ferroptosis inducer. Erastin exhibits the mechanism of ferroptosis induction related to ROS and iron-dependent signaling. Erastin inhibits voltage-dependent anion channels (VDAC2/VDAC3) and accelerates oxidation, leading to the accumulation of endogenous reactive oxygen species. Erastin also disrupts mitochondrial permeability transition pore (mPTP) with anti-tumor activity. Furthermore, Erastin can block the uptake of cystine mediated by SLC7A11 and also spares UMRC6-EV and -C91A cells from disulfidptosis under glucose starvation.

For research use only. We do not sell to patients.

CAS No. : 571203-78-6

Size Price Stock Quantity
1 mg In-stock
1 mg * 5 In-stock
1 mg * 10 In-stock
5 mg   Get quote  
10 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 526 publication(s) in Google Scholar

Other Forms of Erastin:

Top Publications Citing Use of Products

515 Publications Citing Use of MCE Erastin

Cell Viability Assay
WB
IF
Proliferation Assay

    Erastin purchased from MedChemExpress. Usage Cited in: Gene. 2023 May 9;873:147468.  [Abstract]

    Erastin (8 μM; 48 h) greatly induces apoptosis and cell death in AGS and BGC-823 cells.

    Erastin purchased from MedChemExpress. Usage Cited in: Gene. 2023 May 9;873:147468.  [Abstract]

    Erastin (8, 16 μM; 48 h) reduces the expression of xCT in AGS and BGC-823 cells.

    Erastin purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2022 Feb;24(2):168-180.  [Abstract]

    Survival rates of MCF10A-RAS cells cultured on stiff or soft Matrigel and treated for 48 h with Erastin (10-30 μM).

    Erastin purchased from MedChemExpress. Usage Cited in: Redox Biol. 2022 Aug;54:102382.  [Abstract]

    After treatment with Ferrostatin-1 (Fer-1, 5 μM) and GW4064 (1 μM) for 2 h, HK2 cells are treated with Erastin (5 μM) for another 24 h. After treatment with Fer-1 and GW4064, the cells are incubated with C11-BODIPY 581/591 (2 μM) and Hoechst 33258 for counterstaining; the images were then immediately visualized by confocal microscopy.

    Erastin purchased from MedChemExpress. Usage Cited in: Redox Biol. 2022 Aug;54:102382.  [Abstract]

    After treatment with Ferrostatin-1 (Fer-1, 5 μM) and GW4064 (1 μM) for 2 h, HK2 cells are treated with Erastin (5 μM) for another 24 h. Protein levels of GPX4 are detected by immunoblotting.

    Erastin purchased from MedChemExpress. Usage Cited in: Clin Transl Med. 2022 Apr;12(4):e752.  [Abstract]

    Representative images of intracellular mitochondrial superoxide level in SW480 and HT29 cells subjected to the stable knockdown of LINC001606 or stably overexpressing LINC001606 after treatment of DMSO, Erastin (10 μM) and RSL3 (2 μM) for 48 h.

    Erastin purchased from MedChemExpress. Usage Cited in: Cell Death Differ. 2020 Sep;27(9):2635-2650.  [Abstract]

    Erastin (10 μM; tail-injected intravenously; for 20 days) treatment of I/R mice significantly increases the protein/mRNA levels of TF and significantly decreased the percentage GSH and protein/mRNA levels of FTH1 and GPX4, but these effects are reversed by Liproxstatin-1 treatment.

    Erastin purchased from MedChemExpress. Usage Cited in: Cell Death Differ. 2020 Sep;27(9):2635-2650.  [Abstract]

    H&E and Masson’s staining of lung tissues show that Erastin (10 μM; tail-injected intravenously; for 20 days) aggravated edema, atelectasis, necrosis, alveolar and interstitial inflammation, and pulmonary fibrosis in I/R mice compared with sham mice, but these effects are reversed in I/R + erastin mice treated with Liproxstatin-1.

    Erastin purchased from MedChemExpress. Usage Cited in: Cell Death Differ. 2021 Apr;28(4):1222-1236.  [Abstract]

    Western blot analysis of the protein expression levels of BCAT2, AMPK, and pAMPK(T172) in Aspc-1, and HepG2 cells treated with Erastin (20 or 10 μM) Vin the absence or presence of AICAR (AMPK activator, 2 mmol/L) and Compound C (AMPK inhibitor, 1 μmol/L).

    Erastin purchased from MedChemExpress. Usage Cited in: Neurotherapeutics. 2020 Oct;17(4):1796-1812.  [Abstract]

    The effect of an inducer or inhibitor of ferroptosis on PC-12 cells. PC-12 cells are treated with 40 μM 6-OHDA in combination with an inducer (1 μM Erastin) of ferroptosis for 24 h. The expression of GPX4, TH, and FTH1 is significantly reduced in cells treated with the combination of erastin and 6-OHDA compared with those treated with 6-OHDA alone.

    Erastin purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2020 Dec 5;888:173574.  [Abstract]

    With the various dosage of ferroptosis inducer Erastin treatment for 24 h, the cell viability is determined by SRB method.

    MCE Biological Validation

    WB
    Cell Viability Assay
      HT-1080 cells were seeded at 60000 cells/well in a 24 well plate and were cultured overnight. Then, cells were treated with Erastin (HY-15763) (0-100 nM) for 24 h, and the expression of GPX-4 was measured. The results indicated that Erastin inhibits GPX-4 expression. Primary antibody: GPX-4 antibody (HY-P80450), GAPDH antibody (HY-P80137).
      HT-1080 cells were seeded at 8000 cells/well in a 96-well plate and were cultured overnight. Then, cells were treated with Erastin (HY-15763) (0-400 nM) for 24 h, and the cell viability was assayed by CCK-8 kit (HY-K0301). The results indicated that Erastin inhibits the cell viability.
      HT-1080 cells were seeded at 8000 cells/well in a 96 well plate and were cultured overnight. Then, cells are treated with 200 nM Erastin (HY-15763) in the presence or absence of Ferrostatin-1 (HY-100579) (Fer-1, 0.5 μM) for 24 h. The results indicated that Fer-1 inhibits the ferroptosis induced by Erastin.
      • Biological Activity

      • Purity & Documentation

      • References

      • Customer Review

      Description

      Erastin is a ferroptosis inducer. Erastin exhibits the mechanism of ferroptosis induction related to ROS and iron-dependent signaling. Erastin inhibits voltage-dependent anion channels (VDAC2/VDAC3) and accelerates oxidation, leading to the accumulation of endogenous reactive oxygen species. Erastin also disrupts mitochondrial permeability transition pore (mPTP) with anti-tumor activity. Furthermore, Erastin can block the uptake of cystine mediated by SLC7A11 and also spares UMRC6-EV and -C91A cells from disulfidptosis under glucose starvation[1][2][3][4][5][6][7][8][9][10][11][12][13][14].

      Cellular Effect
      Cell Line Type Value Description References
      BJ IC50
      0.9 μM
      Compound: erastin
      Induction of cell death in human BJ cells expressing TERT, LT, ST and RAS G12V mutant genes cells in presence of PD-98059 by trypan blue exclusion method
      Induction of cell death in human BJ cells expressing TERT, LT, ST and RAS G12V mutant genes cells in presence of PD-98059 by trypan blue exclusion method
      [PMID: 17568748]
      BJ IC50
      0.9 μM
      Compound: erastin
      Induction of cell death in human BJ cells expressing TERT, LT, ST and RAS G12V mutant genes cells in presence of MEK inhibitor 2 by trypan blue exclusion method
      Induction of cell death in human BJ cells expressing TERT, LT, ST and RAS G12V mutant genes cells in presence of MEK inhibitor 2 by trypan blue exclusion method
      [PMID: 17568748]
      BJ IC50
      2 μM
      Compound: erastin
      Induction of cell death in human BJ cells expressing TERT, LT, ST and RAS G12V mutant genes cells in presence of MEK 1/2 inhibitor by trypan blue exclusion method
      Induction of cell death in human BJ cells expressing TERT, LT, ST and RAS G12V mutant genes cells in presence of MEK 1/2 inhibitor by trypan blue exclusion method
      [PMID: 17568748]
      BJ IC50
      2.6 μM
      Compound: erastin
      Induction of cell death in human BJ cells expressing TERT, LT, ST and RAS G12V mutant genes in presence of MEK inhibitor by trypan blue exclusion method
      Induction of cell death in human BJ cells expressing TERT, LT, ST and RAS G12V mutant genes in presence of MEK inhibitor by trypan blue exclusion method
      [PMID: 17568748]
      BJ IC50
      31.2 μM
      Compound: erastin
      Induction of cell death in human BJ cells expressing TERT, LT, ST and RAS G12V mutant genes in presence of U0126 by trypan blue exclusion method
      Induction of cell death in human BJ cells expressing TERT, LT, ST and RAS G12V mutant genes in presence of U0126 by trypan blue exclusion method
      [PMID: 17568748]
      Calu-1 IC50
      4 μM
      Compound: erastin
      Inhibition of human Calu1 cells expressing KRAS with activating mutations by trypan blue exclusion assay
      Inhibition of human Calu1 cells expressing KRAS with activating mutations by trypan blue exclusion assay
      [PMID: 17568748]
      CCF-STTG1 IC50
      200 nM
      Compound: ERA
      Inhibition of Xct in human CCF-STTG1 cells assessed as glutamate release after 2 hrs by fluorometry
      Inhibition of Xct in human CCF-STTG1 cells assessed as glutamate release after 2 hrs by fluorometry
      [PMID: 26231156]
      HT-1080 IC50
      1 μM
      Compound: erastin
      Induction of cell death in human HT1080 cells in presence of PD-98059 by trypan blue exclusion method
      Induction of cell death in human HT1080 cells in presence of PD-98059 by trypan blue exclusion method
      [PMID: 17568748]
      HT-1080 IC50
      1.3 μM
      Compound: erastin
      Induction of cell death in human HT1080 cells in presence of MEK inhibitor 2 by trypan blue exclusion method
      Induction of cell death in human HT1080 cells in presence of MEK inhibitor 2 by trypan blue exclusion method
      [PMID: 17568748]
      HT-1080 IC50
      2.5 μM
      Compound: erastin
      Induction of cell death in human HT1080 cells in presence of MEK inhibitor by trypan blue exclusion method
      Induction of cell death in human HT1080 cells in presence of MEK inhibitor by trypan blue exclusion method
      [PMID: 17568748]
      HT-1080 IC50
      3.4 μM
      Compound: erastin
      Induction of cell death in human HT1080 cells in presence of U0126 by trypan blue exclusion method
      Induction of cell death in human HT1080 cells in presence of U0126 by trypan blue exclusion method
      [PMID: 17568748]
      HT-1080 IC50
      6 μM
      Compound: erastin
      Induction of cell death in human HT1080 cells in presence of MEK 1/2 inhibitor by trypan blue exclusion method
      Induction of cell death in human HT1080 cells in presence of MEK 1/2 inhibitor by trypan blue exclusion method
      [PMID: 17568748]
      In Vitro

      Erastin (10 μM; 24 h) triggers ferroptosis in ectopic endometrial stromal cells (EESCs), and increases the total ROS level at 9 h[1].
      Erastin shorts mitochondria and increases membrane density in EESCs[1].
      Erastin (10 μM; 9 h) decreases the mRNA expression levels of iron-related proteins, such FPN (iron exporter) in EESCs. However, FPN overexpression significantly inhibits erastin-induced ferroptosis in EESCs[1].
      Erastin (10 μM; 24 h) induces mitochondrial permeability transition pore (mPTP) opening in HT-29 colorectal cancer cells[2].
      Erastin (30 μM; 72 h) significantly inhibits the growth of HT-29 colorectal cancer cells[2].
      The molecular mechanism by which Erastin induces ferroptosis is related to genes regulating iron or mitochondrial fatty acid metabolism. Includes ribosomal protein L8, iron response element binding protein 2 (IREB2), ATP synthase F0 complex subunit C3, citrate synthase, tetrapeptide repeat domain 35, and acyl-CoA synthetase family member 2 (ACSF2)[3].
      Note:
      1. Different cell lines may have different sensitivity to a same compound. As reported, A549, HCT116, HepG2, H1299 cells may be insensitive to Erastin[3][4][5].
      2. Erastin is unstable in solution. Freshly prepared is recommended.

      Ferroptosis-sensitive Cell Lines

      Ferroptosis-sensitive Cells Test Conditions
      SKOV3[6] 5-20 μM; 1-7 days
      OVCA429[6] 5-20 μM; 1-7 days
      MCF10A-RAS[7] 0-30 μM; 48 h
      HT-22 neuron[8] 500 nM; 16 h
      NCI-H508[9] 0.1-10 μM; 48 h
      LoVo[9] 0.1-10 μM; 48 h
      LS513[9] 0.1-10 μM; 48 h
      SW480[9] 0.1-10 μM; 48 h
      SW620[9] 0.1-10 μM; 48 h
      SW1116[9] 0.1-10 μM; 48 h
      DLD-1[9] 0.1-10 μM; 48 h
      Caco-2[9] 0.1-10 μM; 48 h
      SW837[10] 0-40 μM; 24 h
      Pfa1[11] 0.1-5 μM; 48 h
      HT-1080[12] 0.1-5 μM; 48 h
      MAD-MB-231[13] 0-100 μM; 72 h; IC50: 9.55 μM
      HCC1937[13] 0-100 μM; 72 h; IC50: 11.58 μM


      Ferroptosis-insensitive Cell Lines
      Ferroptosis-insensitive Cells Test Conditions
      HCT116[11] 0-40 μM; 24 h
      SW48[11] 0-40 μM; 24 h
      HepG2[5] 0-20 μM; 24 h
      MDA-MB-436[13] 0.1-25 μM; 24 h
      HT-29[13] 0.1-25 μM; 24 h
      U-373[13] 0.1-25 μM; 24 h

      MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

      Cell Viability Assay[1]

      Cell Line: Normal endometrial stromal cells (NESCs) and endometrial stromal cells (EESCs)
      Concentration: 0, 0.5, 0.8, 1, 1.5, 2, 2.5, 5, 10 μM
      Incubation Time: 24 hours
      Result: Induced cell detachment and overt death in EESCs, but not NESCs.

      Apoptosis Analysis[1]

      Cell Line: EESCs infected with adenovirus expressing FPN cDNA (co-incubation for 24 hr)
      Concentration: 0, 0.5, 1.5, 2.5, 5 and 2.5 μM
      Incubation Time: 24 hours
      Result: Induced ferroptosis by decreasing the levels of total ROS and lipid ROS. And reversed by the overexpression of FPN in adenovirus-infected cells.
      In Vivo

      Erastin can be used in animal modeling to construct ferroptosis induction model.

      Erastin (40 mg/kg; i.p.; once every 3 days for 2 weeks) suppresses endometriotic implants in the mouse endometriosis model, indicating Erastin regresses ectopic lesions by trigging ferroptosis[1].
      Erastin (10 mg/kg, 30 mg/kg; i.p.; once daily for 4 weeks) suppresses HT-29 xenograft growth in SCID mice, with more potent efficacy under 30 mg/kg treatment[2].

      MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

      Animal Model: Mouse model of endometriosis[1]
      Dosage: 40 mg/kg
      Administration: Intraperitoneal injection; once every 3 days for 2 weeks
      Result: Showed little impact on body weight of mice and hair of mice displayed neat and glossy.
      Reduced the volume of ectopic lesions.
      Molecular Weight

      547.04

      Formula

      C30H31ClN4O4

      CAS No.
      Appearance

      Solid

      Color

      White to off-white

      SMILES

      O=C1N(C2=CC=CC=C2OCC)C(C(N3CCN(C(COC4=CC=C(Cl)C=C4)=O)CC3)C)=NC5=C1C=CC=C5

      Shipping

      Room temperature in continental US; may vary elsewhere.

      Storage
      Powder -20°C 3 years
      4°C 2 years

      *The compound is unstable in solutions, freshly prepared is recommended.

      Solvent & Solubility
      In Vitro: 

      DMSO : 12.5 mg/mL (22.85 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

      H2O : < 0.1 mg/mL (insoluble)

      Preparing
      Stock Solutions
      Concentration Solvent Mass 1 mg 5 mg 10 mg
      1 mM 1.8280 mL 9.1401 mL 18.2802 mL
      5 mM 0.3656 mL 1.8280 mL 3.6560 mL
      View the Complete Stock Solution Preparation Table

      * Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

      • Molarity Calculator

      • Dilution Calculator

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      Mass
      =
      Concentration
      ×
      Volume
      ×
      Molecular Weight *

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      Concentration (start)

      C1

      ×
      Volume (start)

      V1

      =
      Concentration (final)

      C2

      ×
      Volume (final)

      V2

      In Vivo:

      Select the appropriate dissolution method based on your experimental animal and administration route.

      For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
      To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
      The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

      • Protocol 1

        Add each solvent one by one:  10% DMSO    90% Corn Oil

        Solubility: ≥ 1.25 mg/mL (2.29 mM); Clear solution

        This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

        Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL Corn oil, and mix evenly.

      • Protocol 2

        Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

        Solubility: ≥ 1 mg/mL (1.83 mM); Clear solution

        This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).

        Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

        Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.

      For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
      The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

      • Protocol 1

        Add each solvent one by one:  15% Cremophor EL    85% Water

        Solubility: 10 mg/mL (18.28 mM); Suspended solution; Need ultrasonic

      In Vivo Dissolution Calculator
      Please enter the basic information of animal experiments:

      Dosage

      mg/kg

      Animal weight
      (per animal)

      g

      Dosing volume
      (per animal)

      μL

      Number of animals

      Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
      Please enter your animal formula composition:
      %
      DMSO +
      +
      %
      Tween-80 +
      %
      Saline
      Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
      The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
      Calculation results:
      Working solution concentration: mg/mL
      Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

      *The compound is unstable in solutions, freshly prepared is recommended.

      The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
      Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
       If the continuous dosing period exceeds half a month, please choose this protocol carefully.
      Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
      Purity & Documentation

      Purity: 99.76%

      References

      Complete Stock Solution Preparation Table

      * Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

      Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
      DMSO 1 mM 1.8280 mL 9.1401 mL 18.2802 mL 45.7005 mL
      5 mM 0.3656 mL 1.8280 mL 3.6560 mL 9.1401 mL
      10 mM 0.1828 mL 0.9140 mL 1.8280 mL 4.5700 mL
      15 mM 0.1219 mL 0.6093 mL 1.2187 mL 3.0467 mL
      20 mM 0.0914 mL 0.4570 mL 0.9140 mL 2.2850 mL
      • No file chosen (Maximum size is: 1024 Kb)
      • If you have published this work, please enter the PubMed ID.
      • Your name will appear on the site.
      Help & FAQs
      • Do most proteins show cross-species activity?

        Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

      Your Recently Viewed Products:

      Inquiry Online

      Your information is safe with us. * Required Fields.

      Product Name

       

      Requested Quantity *

      Applicant Name *

       

      Salutation

      Email Address *

       

      Phone Number *

      Department

       

      Organization Name *

      City

      State

      Country or Region *

           

      Remarks

      Bulk Inquiry

      Inquiry Information

      Product Name:
      Erastin
      Cat. No.:
      HY-15763
      Quantity:
      MCE Japan Authorized Agent: